By the Top Tier Newswire AI Desk · September 22, 2026 at 3:04 PM ET · reviewed against 36 wire stories
VIKING THERAPEUTICS (VKTX) is up +37.09% in the latest session. Our newswire has captured 36 stories on VKTX across 20 sources in the last 36 hours, with AI sentiment reading bullish (avg 65/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why VKTX stock is up today
Viking Therapeutics stock rose 37.09% to $41.28 on Tuesday, driven by positive clinical data for its lead obesity drug candidate, VK2735. The drug demonstrated strong weight loss maintenance with less frequent dosing, sparking renewed investor interest and analyst optimism. The stock opened with a 5.3% gap up and reached a session high of $45.93 before settling near $41.05.
What Happened
Viking Therapeutics released data showing that VK2735, a GLP-1/GIP drug, helped patients retain up to 97% of prior weight loss with every-other-week dosing and approximately 90% with monthly dosing. This maintenance performance has drawn comparisons to Eli Lilly’s Zepbound and has positioned Viking as a potential challenger to the current obesity drug market leaders. Analysts at Oppenheimer raised the price target for Viking to $120 from $100, citing the “impressive” data. Goldman Sachs also reiterated its positive stance on the stock. The news came as Viking’s stock was already on a recent upward trajectory, having gained 20.7% over the past eight sessions.
What The Data Shows
The stock opened at $31.71 and traded as high as $45.93 before settling at $41.05. Volume surged to 31.5 million shares, 14.5 times the 3-month average. The stock has traded between $24.52 and $43.15 over the past 52 weeks. Viking has no earnings to date, with an EPS TTM of -4.67, and carries a market cap of $3.4 billion. On the options front, call premiums totaled $8.2 million in the last 36 hours, with the largest single print valued at $3.4 million.
What To Watch
The stock is currently trading near its 52-week high of $43.15. Investors may watch for further analyst commentary and potential catalysts in the coming weeks. No earnings date is scheduled at this time, but coverage breadth remains high, with 36 stories from 20 sources in the last 36 hours.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
Goldman Sachs reiterates Viking Therapeutic stock rating on obesity drug data
Goldman Sachs reiterates Viking Therapeutic stock rating on obesity drug data
6h agoYahoo TopBULLISH 73Product/PR
Viking Soars Alone as Obesity Complex Shrugs at Strong GLP-1 Results
Viking Therapeutics surged more than 26% on fresh GLP-1 maintenance data while every major obesity peer from Eli Lilly to Novo Nordisk barely registered a pulse, raising a pointed question about whether this catalyst belongs to Viking alone or signals something bigger.
6h agoQuartzBULLISH 58Product/PR
Viking Therapeutics VK2735 weight loss maintenance trial results - qz.com
7h agoThe FlyBULLISH 73Analyst
Oppenheimer ups Viking Therapeutics target to $120 on ‘impressive’ data
7h agoThe FlyBULLISH 61Analyst
Viking Therapeutics price target raised to $120 from $100 at Oppenheimer
8h agoMarketWatchBULLISH 67Product/PR
This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month
Viking Therapeutics is developing VK2735, a GLP-1/GIP drug that could compete with Eli Lilly’s Zepbound. Its stock is soaring.
8h agoBusiness InsiderBULLISH 73Product/PR
Viking Thera adds most since 2024 after “clean” safety data for obesity drug
Viking Therapeutics (VKTX) stock surges as analysts react to data from a maintenance study for the company
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →